The alkylphospholipid hexadecylphosphocholine (HePC), member of a new class of antineoplastic drugs, has been previously shown to exert cytotoxic effects on neoplastic cell lines in vitro, and a selective antineoplastic activity has been reported after topical apflication of He PC in I/ivo, in particular on skin metastases 0 human mammary carcinomas. Preliminary observations suggest that HePC might also be beneficial in the treatment of non-neoplastic skin diseases characterized by epidermal hyperplasia such as psoriasis. Therefore, we investigated whether HePC might inhibit the proliferation of normal human keratinocytes, and whether its effects might be dependent upon the proliferative status of the treated cells. Moreover, its effects on phosphatidylcholine biosynthesis were studied in keratinocytes. HePC dosedependently decreased cell numbers, thymidine incorporation, and protein synthesis when applied during the growth phase of keratinocytes grown in serum-free medium, with a F or more than 30 years, lysophosphatidylcholines and ether-linked lysophosphatidylcholines (etherlipids) have been known to exert antineoplastic effects [1]. Investigations on the minimal structural requirements for lysophosphatidylcholines and related compounds to exert an antitumoral action revealed alkylphosphocholines as a new class of antineoplastic drugs [1, 2] that show antitumoral properties as potent as those of the well known lysophosphatidylcholines 1-0-octadecy l-2-0-methyl-rac-glycero-3-phosphocholine (Et-18-OCH 3 ) and BM41.440 (21.
The alkylphospholipid hexadecylphosphocholine (HePC), member of a new class of antineoplastic drugs, has been previously shown to exert cytotoxic effects on neoplastic cell lines in vitro, and a selective antineoplastic activity has been reported after topical apflication of He PC in I/ivo, in particular on skin metastases 0 human mammary carcinomas. Preliminary observations suggest that HePC might also be beneficial in the treatment of non-neoplastic skin diseases characterized by epidermal hyperplasia such as psoriasis. Therefore, we investigated whether HePC might inhibit the proliferation of normal human keratinocytes, and whether its effects might be dependent upon the proliferative status of the treated cells. Moreover, its effects on phosphatidylcholine biosynthesis were studied in keratinocytes. HePC dosedependently decreased cell numbers, thymidine incorporation, and protein synthesis when applied during the growth phase of keratinocytes grown in serum-free medium, with a F or more than 30 years, lysophosphatidylcholines and ether-linked lysophosphatidylcholines (etherlipids) have been known to exert antineoplastic effects [1] . Investigations on the minimal structural requirements for lysophosphatidylcholines and related compounds to exert an antitumoral action revealed alkylphosphocholines as a new class of antineoplastic drugs [1, 2] that show antitumoral properties as potent as those of the well known lysophosphatidylcholines 1-0-octadecy l-2-0-methyl-rac-glycero-3-phosphocholine (Et-18-OCH 3 ) and BM41.440 (21. The most prominent representative of this group of compounds, hexadecylphosphocholine (HePC ; Fig 1) , exerts a pronounced cytotoxic action on different neoplastic cell lines in vitro [3, 4] and a selective antineoplastic activity in vivo (5 -7] . In particular, topical application of HePC has been shown to be successful in the treatment of skin metastases of human mammary carcinomas [8] , and its activity against mammary tumors was superior to that of cyclophosphamide in animal experiments [5] . Compared with other alkylphosphatidylcholines, HePC has the advantage that it is only slowly minimal inhibitory dose of 10-7 molll for thymidine incorporation, 3 X 10-7 molll for cell numbers, and 10-6 molll for 35S-methionine incorporation. No major differences were observed when keratinocytes were grown under high-Ca++ conditions. In contrast, slowly proliferating confluent keratinocyte cultures showed growth inhibition only after molll HePe. Phosphatidylcholine biosynthesis was dosedependently inhibited by HePC with a half inhibitory concentration of 3 X 10-6 mol/I, and with translocation of the rate-limiting enzyme, CTP:phosphocholine cytidylyltransferase, to the cytosol, where the enzyme is inactive. These data show a pronounced antiproliferative effect of He PC also on proliferating non-malignant keratinocytes, and are compatible with its possible action on hyperproliferative skin disorders. Key words: hexadecylphosphocholinelphosphatidylcho-
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and poorly metabolized, mainly by cleavage of the choline head group [9] . Moreover, blood samples of patients treated with HePC were free of this compound, demonstrating lack of absorption even after extensive topical treatment [10] .
These data suggest that HePC might be a useful agent in the adjuvant therapy of skin metastases of mammary carcinomas, but possibly also of cutaneous malignancies such as cutaneous T-cell lymphomas and others [10] . Moreover, as it had been claimed that HePC exerts a selective anti proliferative effect on proliferating neoplastic cells ill vivo [5 - 71 and as we and others had previously shown that HePC inhibits protein kinase C ill vitro [11] [12] [13] that is involved in the regulation of keratinocyte proliferation, it was tempting to speculate whether HePC might also be effective in non-neoplastic skin diseases characterized by epidermal hyperplasia such as psoriasis . As preliminary clinical observations were compatible with this hypothesis (WR, personal observation), we aimed to investigate whether HePC might also inhibit the growth of nontransformed, normal human keratinocytes, and whether a potential antiproliferative effect of HePC might be dependent upon the hyperproliferative status of the treated cells. As alkylphospholipids are readily bound to serum proteins such as serum albumin or lipoproteins, lowering their uptake rate into the cells and decreasing their biologic activity [1, 14, 15] , all experiments were carried out on keratinocytes grown in serum-free medium. To exclude a dependency of HePC effects upon the Ca++ concentration, comparative experiments were performed in low-Ca++ and in high-Ca++ medium. Moreover, we were interested in whether HePC might exert its antiproliferative effects by interference with the biosynthesis of 0022-202X!94!S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. incorporation into ph osphatidylcholine and the intracellular loca lization of th e rate-limitin g enzyme, CTP:phosphocholine cytidyly ltransferase, were studied und er th e influe nce of HePe.
MATERIALS AND METHODS
Reagents (Methy!-3H]choline chl oride (2.8 -3.1 TBqjmmol), ' H-thymidi ne (50 -70 Cijmmol) , '5S-methionine (37 TBqjmmol), and [Methyl-14C] -phosphoc holin e (20 Bq/ nmol) were purchased from Amers ham (Braunschwei g, Germany). Hexadecylphosphoc holine (HePC) was sy nthesized in twO steps from th e tetra-n-butyl-ammonium salt of phosphocholine and I-bromohexadeca ne, and purified by co lumn chromatography on silica gel as described (17] . Dith iothreitol, digitonin, and lipid standards were from Sigma.
Cell Culture Six-millimeter punch biopsies were obtained from the lower back of health y volunteers, and normal human epidermal keratinocyees were iso lated as described [18] . Keratinocytes were then suspended in serum-free keratinocyte basa l medium (Clonetics, San Diego, CA), supplemented with 10 ng/ml epidermal grow th factor,S J.Lg/ml insu lin, 0.5 J.LM hydroco rtisone, 50 J.Lg/ml bovine pituitary extract, 100 J.Lg/ml penicillin/ strepto myci n, and 2.5 J.Lg/ml fun gizone (all purchased from C lonetics), and were pl ated in 80-mm plastic Petri dishes (Costa r, Cambridge, MA) with a seeding density of 1 X 10 4 viable cells/cm 2 . The cells were incubated at 37° C in 100% humidity in an atmosphere of 95% air, 5% CO 2 , The medium was replaced every 2 d, and the ce lls were passaged before conflu ency. For all experiments, kerati nocytes were used at seco nd passage.
Proliferation Assays All proliferation assays were performed on keratinocytes grow n in low-Ca-H-medium (0.15 mM) and on keratinocytes grown in high-Ca-H-medium (1.1 mM). For determination oPH-thymidine inco rporation into DNA, second-passage kcratinocytes were seeded in 24-wcll tissue culture clusters (Costar) with a seeding density of 1 X 10' cells/cm 2 . The following day, tripli ca te cultures were incubated either w ith medium alone or with medi um contai nin g 10-4 _10- 8 Moljl H ePC. Fresh medi um containing H ePC was added after 2 d. After 4 d, keratinocyte cultures were incubated for 6 h at 37"C with 1 J.l Cijml ' H-thymidine (50-70 CijmM). The incorporatio n oPH -thymidine was sto pped by medium aspiration followed by two washes wi th co ld phosphate-buffered saline (PBS) and the addition of co ld 6% trichl oroacetic acid. The incorporated radioactivity was determined by liquid scintillation counting as described elsew here [1 9]. and the results show n represent mean values ± SO of three separate expe rim ents conducted in duplica te.
In addition, cell prolifera tion was assessed by the MUH flu orescence assay [20] . Keratinocytes were seeded in 96-multiwell plastic tissue culture plates (Falcon) with a density of 5 X 10' cells/cm 2 and treated with HePC as described above. Five we lls for each co ncentration were treated identically. After 4 d, th e cell s were washed twice with PBS and were incubated with 100 J.l1 4-methylumbe lli fery l heptanoate (MUH ; Serva, H eidelberg, Germany; 100 J.lg/ml in PBS) at 37"C for 1 h. The resulting flu orescence was measured using a Fluoroscan II devicc (Flow Laboratory, Meckenh eim, Germany) as previously described [20, 21] . MUH is hydro lyzed by ce ll esterases, and the amount of measurcd flu orescence is proportional to the nlllnbcr of vi able cc ll s (20] . The resu lts are given as absolute fluorescence units (AFU) and were calcul ated as mea ns ± SO fro m fiv e different wells. The experiments were repea ted with identica l res ults.
In furth cr experiments, the time dependcncy of HePC cffects on keratinocyte proliferation was exa mined by adding 10-5 _ 10-7 M HePC for 2, 4, 6, 8,24,48,72, or 96 h. Thercafter, 'H-th ymidine incorporatio n and MUH fluoresce nce were detcrmined as described above. In addition, co nfluent cultures were trea ted with HePC (10-4 -10-8 M) for 4 d, to test wh eth er
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HePC effects o n keratin ocyte proliferation were dependent upon the proliferative status of the treated ceLls.
Determination of Protein Synthesis Keratinocytes were treated with HePC in various concentrati ons for 4 d as described above. During the last 12 h of culture, '5S-methi oni ne (10 J.LCijml) was added to the cultures. Thereafter, protcin-bound radioactivity was measured by acid precipitation using a modification of the meth od of Mans and N ovelli [22] .
Determination of Phosphatidylcholine Biosynthesis Keratinocytes were treated with pulse-medium alone or with pu lsc-mediu m containin g HePC (10-4 _10- 6 Mol/ I) for 6 h. Pulse-medium contained [methyl-'HJcholmc, 2.5 ,IlCi/ml. Cells were washed twice wit h ice-cold PBS (pH 7.2) and harvested, fo llowed by mod ifi ed lipid extraction accord ing to Bligh and Dyer [23] . After lyop hil ization of tbe cells, 50,111 methano l, 25 tLl chl oroform, and 20 J.L I water were added. Samples were stirred for 2 min on a vortex-mixer a nd centrifu ged at 13,000 X g for 10 min. Phase separation was accomplished by addition of 25 J.LI chloroform and 25 ,111 water. The suspension and centri fugatio n steps werc repeated, and 15.ul of the chloroform phases were applied to si lica ge l 60 high-performance thin-layer chromatography I?lates usmg a HPTLC applica tor (Linomat III; Camag, Berli n, Germany). LIpIds were separated accordi ng to Touchstone el al [24] , using th e solvent chlorofo rm/met hanoljaceti c acid/ water (25:15:4:2, by volume). RadIOaC tiVIty was quantified by use of a thin-layer chromatography scan~er (Berthold LB 2821 HR, Wddbad, Germany). Phospholipids were Identified by caltbratmg the scanner with known standards.
Measurement of the Distributi<: 1D of CTP:Phospbocholine Cytidylyltransferase The re leasc of cytldylyltransferase fro m keratinocytes was measured as described (25] . Cells were incubated for 6 h in 35-mm dishes with medium alone (control) or suppl emented wi th 3 X 10-6 Moljl HePC. Cell s were then washed tw ice with 1 ml icc-cold PBS, and all the fo ll owing steps were . carried out at 4 DC. Digitonin buffer (150 J.lI) containing 50 mmoljl Tns-H C I (pH 7.4),150 mmoljl N aCI, 1 mmol/I ethylenediarninetetraacetic acid (EDTA), 2 mmoljl dithiothreitol, 1 mmoljl phenylmethylsulfonyl fluorid e (PMSF) , and 0.5 g/I digitonin was added. After incubation for 3 min, th e digitonin supernatant was carefully removed. Undissolved digi tonin w~s pelleted at 2500 X .g for 5 min. The remaining ghosts of the cells m the dIshes we re was hed WIth 500 J.lI PBS, harvested in 35 J.LI buffer as described above (the harves tin g buffer contai ned 0.03% Triton X-IOO and ~o digitonin), and were th en homogeni zed usi ng a dounce with a tight-fittll1g plunger (~ra un , Melslll:gen, Germany). Cytidylyltransferase activi ty was measured 111 the dlgltonm superna tants and in the cell ghost homogenates by a mod~fied ~ethod of Sohal and Cornell [26] as described recently [25] . The reaction mIxture co ntamcd 50 m111ol/ 1 Tris-HCI, pH 7.4,0.03% Triton X-I00, 100 mmoljl N aCl, 10 mmoljl MgCI2' 3 mmol/I CTP, 1.5 mmol/I [methyl.-14CJ-phosphocholinc (20 Bqjnmol), liposomes (400 IllUoljll?hosphatldylcholme/400 J.lmoljl olcic ac id), a.nd 10 III of enzyme preparatIon m a final volumc of 55 J.ll. After incubating for 30 min at 37 D C, the reactlon was stol?ped by freez in g the sa mples in liquid nitrogen. The saml:'l es were Iyophdlzcd, dissolved in 20 J.LI methanol/ water (1 : I , v / v), and apphed t o HPTLC plates. After developing th e plates in a so lvent system con tammg ~ethanoIj0.6% N aC1j25 % aq ueous NH, (8: 5: 1, by volume), the. radIOactIVIty was determined by radioscanning. One unit of enzyme activIty IS de~ned as nmol of COP-cholin e formed per min. From th e data, the dlstnbutlOn of cytoso lic and membrane-bound cy tid ylyltransferase actiVIty was calculated for each dish.
RESULTS
HePC Effects on Keratinocyte Proliferation and Protein
Synthesis Treatment of second-passage keratinocytes with H ePC for 4 d under serum-free, low-Ca++ conditions induced a dose-dependent inhibition of cell pro liferation (Fig 2A) . The minima.1 inhibitory HePC dose was 10-7 M o ll l for thymidine incorporatIon and 3 X 10- 7 Moljl for the MUH assay. Complete inhibition of thymidine i ncorpo ration was o bserved after 10-6 Moljl HePC, and after 10-5 Moljl , no viable keratinocytes were detectab le. In addition, H ePC dose-dependently inhibited cellular protein synthesis, as shown by a significant decrease of methionine incorporation with a minimal inhibitory dose of 10-6 Moljl (Fig 2B) .
In a second series of experiments, kerati nocytes were grow n under serum-free, hi g h-Ca++ conditions and treated identically with HePC to see whether the antiproliferative effects of HePC might be dep e ndent upon the Ca++ concentration in th e culture m edium. We fo und th at th e dose-dep endent dec rease of cellnum-% control 120 --l.. bers was not influenced by increasing Ca++ concentrations (Fig 3) , whereas there was a slight increase in the minimal effective dose necessa. ry to inhibit thymidine incorporation, as compared to lowCa++ conditions. The inhibitory effect of HePC on keratinocyte proliferation was time-dependent, as shown in Fig 4. Treatment with Molll HePC inhibited thymidine incorporation after only 2 h, with a maximum effect after 72 h (Fig 4B) , whereas a decrease of cell numbers, as measured by the MUH assay, was not observed until 48 h later (Fig 4A) . In contrast, inhibition of thymidine incorporation by Molfl HePC was observed after 48 h (Fig 4B) , with decreasing cell numbers after 72 h (Fig 4A) . The earliestinhibitory effect on thymidine incorporation by treatment with Molfl HePC was seen after 72 h, whereas cell numbers remained unchanged for up to 96 h (Fig 4A,B) .
To prove the hypothesis that the growth inhibitory effect of HePC on keratinocytes might be dependent on the proliferative status of the celis, keratinocytes were grown under low-Ca++ conditions until confluency and were then treated with HePC for 4 d. Indeed, confluent cultures that showed only minimal proliferation, as determined by thymidine incorporation and by the MUH assay, THE JOURNAL OF INVESTIGATIVE DERMATOLOGY were much less sensitive to HePC as compared to cultures treated during the logarithmic growth phase. HePC in concentrations up to 10- 4 Molll did not decrease cell numbers, and the thymidine incorporation was only reduced after Molll HePC (data not shown).
HePC Effects on Keratinocyte Phosphatidylcholine Biosyn· thesis To determine the effect of HePC on phosphatidylcholine biosynthesis of keratinocytes, we labeled the cells with [methyl-3H)-choline and measured the incorporation of label into the organic phase of the cell extract. As demonstrated by HPTLC separation and radioscanning, approximately 95% of the label in the organic phase comigrated with the phosphatidylcholine standard and 5% with the sphingomyelin standard (data not shown). Treatment of confluent second-passage keratinocyte cultures with HePC for 6 h dose-dependently inhibited the phosphatidylcholine biosynthesis with a half inhibitory concentration of 3 X 10-6 Molll and a maximum inhibition observed after 3 X 10-5 Molfl (Fig 5) . This inhibition of choline incorporation into phosphatidylcholine corresponds to the data obtained on the subcellular distribution of the rate-limiting enzyme, CTP: phosphocholine cytidylyl transferase (Fig 6) . HePC treatment resulted in a translocation of this enzyme to the cytosol, where the enzyme is inactive.
DISCUSSION
It was shown recently that the phospholipid analogue, hexadecylphosphocholine (HePe), exerts an antineoplastic action in vitro and in vivo [3 -7] , especially in the to£ical treatment of skin metastases of human mammary carcinoma [8J. The present study demonstrates that HePC also inhibits the proliferation of non-transformed, normal human epidermal keratinocytes under serum-free culture conditions. This was shown by a time-and dose-dependent reduction of the number of viable cells, as determined by the MUH fluorescence assay [20] , as well as by inhibition of the incorporation of3H-thymidine into DNA and by inhibition of protein synthesis, as determined by 35S-methionine incorporation.
These data suggest that the antiproliferative effect of HePC ill vitro is not selective for neoplastic cells. Moreover, the minimal concentrations necessary to reduce keratinocyte proliferation were markedly lower than those described for neoplastic ceil lines ill vitro [3,4,12J . This can be explained in part by the use of serum-free media in these experiments, as it had been reported that alkylphospholipids are readily bound to serum albumin and serum lipoproteins, decreasing their uptake rate into the cells [1, 14, 15) . Additional experiments showed that by using media supplemented with 10% fetal calf serum, higher concentrations of HePC were needed for keratinocyte growth inhibition (data not shown). It did not It has been claimed that the i~1 vivo antiproliferative effects of HePC may be specific for neoplastic cells [5 -7] . As neoplastic ceils are usually characterized by enhanced cell proliferation, as compared to surrounding cellular elements, we hypothesized that the growth-inhibiting capacity of HePC might be correlated to. the proliferative status of the treated cells. Indeed, confluent keratmoeyte cultures that showed only minimal proliferative activity were much less sensitive to HePC than cultures treated during the logarithmic growth p hase. Therefore, the antiproliferative action of HePC seems to be rather selective for rapidly proliferating celis, and it is tempting to speculate that HePC might also be effective in non-neoplastic skin disorders characterized by epidermal hyperplasia such as psoriasis. Preliminary clinical observations after topical application of HePC are compatible with this hYfothesis.
The mechanisms of anti proliferative action 0 alkylphospholipids have not yet been completely elucidated. We and others have shown that HePC inhibits protein kinase C irl vitro [11] [12] [13] , an enzyme involved in the regulation of cell proliferation [27] . How- ever, our previous investigations suggested an additional mechanism for the effects of HePC on Madin-Darby canine kidney ceils, demonstrating inhibition of phosphatidylcholine biosynthesis [16, 25] . The present study demonstrated that HePC dose-dependently inhibited the biosynthesis of phosphatidylcholine in keratinocytes, suggesting plasma membranes as primary targets for the action of HePe. The decreased phosphatidylcholine biosynthesis was due to inactivation of the rate-limiting enzyme, CTP:phosphocholine cytidylyltransferase, by translocation from membranes to the cytosol where the enzyme is inactive. Moreover, the antiproliferative effect of HePC was not markedly modulated by increasing the Ca++ concentration of the culture media.
These Control HePC Figure 6 . Distribution of CTP:phosphocholine cytidylyltransferase in keratinocytes grown ill serum-free, low-Ca++ medium after treatment with 3 X 10- 6 Molll HePC or medium control for 6 h. Cytidylyltransferase activity was measured in the digitonin supernatants and in the cell membrane homogenates as described in Materials alJd Methods. The distribution of cytidylyltransferase was calculated in percent of total activity. Bars, mean ± SO.
inhibiting the proliferation of normal human epidermal keratinocytes. Unlike other cytostatic drugs, HePC-induced growth inhibition includes the inactivation of the membrane-bound enzyme CTP:phosphocholine cytidylyltransferase, thereby inhibiting phosphatidylcholine biosyn~hesis. Because the .antip:oli~erative effect of HePC il1 vitro was fairly specific for rapidly dlvldmg keratlnocytes, it is conceivable that HePC might also inhibit epidermal hyperplasia without markedly influencing surrounding normal tissue after topical treatment ill vivo. Indeed, preliminary data confirm a beneficial effect of topical HePC application on skin metastases of mammary carcinomas without induction of epidermal atrophy in the surrounding areas [5, 8] . As blood samples of patients treated with HePC were free of this compound, demonstrating lack of absorption even after extensive topical application [10] , other skin disorders with neoplastic or non-neoplastic cellular hyperplasia might also be appropriate targets for topical therapy with HePC. 
